Treatment With Sildenafil, Bosentan, or Both in Children and Young People With Idiopathic Pulmonary Arterial Hypertension and Eisenmenger's Syndrome
| Autor: | Marina Blanco-Aparicio, Constancio Medrano-López, Inés Raposo-Sonnenfeld, Isabel Otero-González, Ángela Ferrer-Barba |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Heart disease Sildenafil Hypertension Pulmonary Vasodilator Agents Piperazines Sildenafil Citrate World health chemistry.chemical_compound Internal medicine medicine Humans In patient Sulfones Child Antihypertensive Agents Sulfonamides S syndrome business.industry Idiopathic Pulmonary Arterial Hypertension Infant Bosentan General Medicine Eisenmenger Complex medicine.disease respiratory tract diseases chemistry Purines Cardiology Female Endothelin receptor business medicine.drug |
| Zdroj: | Revista Española de Cardiología (English Edition). 60:366-372 |
| ISSN: | 1885-5857 |
| DOI: | 10.1016/s1885-5857(07)60169-8 |
| Popis: | Introduction and objectives. Pulmonary arterial hypertension carries a poor prognosis in both adult and pediatric patients. Current understanding of the mechanisms underlying pulmonary arterial hypertension has enabled the rapid development of appropriate drugs, such as endothelin receptor antagonists and 5-phosphodiesterase inhibitors, that can be administered orally and which are generally well tolerated. The aims of the present study were to evaluate functional class and exercise capacity following long-term treatment with sildenafil or bosentan in patients with idiopathic pulmonary arterial hypertension and Eisenmenger’s syndrome and to compare results in the 2 groups. Methods. Seven patients were included in the pulmonary arterial hypertension study, and diagnoses of idiopathic pulmonary arterial hypertension were confirmed. Five patients were treated with sildenafil, while 2 received bosentan. The 5 patients with a non-restrictive ventricular septal defect and pulmonary arterial hypertension were treated with sildenafil. In 1 patient, bosentan was added to the sildenafil. Results. Both sildenafil and bosentan significantly improved exercise capacity in patients with idiopathic pulmonary arterial hypertension. The treatment effect was less in those with Eisenmenger physiology. Although the improvement in World Health Organization functional class was greater in patients with idiopathic pulmonary arterial hypertension, it was significant in both groups. Conclusions. Long-term treatment with sildenafil and bosentan improved both exercise capacity and functional class in patients with idiopathic pulmonary arterial hypertension and in those with hypertension due to congenital heart disease. The changes were more marked in patients with idiopathic pulmonary arterial hypertension. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect